PAX Unveils FLOW, the Brand’s Most Powerful Dry Herb Cannabis Vaporizer Ever
5.8.2025 14:15:00 CEST | Business Wire | Press Release
PAX today announced the highly anticipated launch of PAX FLOW, the latest innovation from the global cannabis brand that pioneered the portable dry herb vaporization category nearly two decades ago. Built for the modern cannabis consumer and connoisseur alike, FLOW introduces a reengineered, true-to-flower experience—delivering combustion-free, next-level vapor performance, superior flavor, intuitive use, and the iconic design aesthetic that is unmistakably PAX.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250805967305/en/
FLOW, PAX's new reengineered, true-to-flower dry herb vaporizer.
“FLOW represents what’s possible when years of market-leading engineering meet a deep understanding of the cannabis plant,” said Justin Tacy, VP of Marketing at PAX. “Our new flagship flower vaporizer is designed to elevate and refine the connoisseurs’ experience with unparalleled vapor performance matching, and even surpassing, traditional combustion methods, while setting a new standard for flower vaporization.”
New Hybrid Heating Technology for Maximum Vapor and Potency
FLOW introduces a reimagined hybrid heating system that blends conduction and convection technologies for even heating and enhanced performance—always without combustion. The result is a rich, smooth, and more flavorful vapor that more efficiently extracts cannabinoids and terpenes. Four optimized heat modes powered by real-time temperature control allow consumers to tailor each session to their preferred taste, potency, and style.
Up to 6x More Airflow for Effortless Draws
A first-of-its-kind, high-rate airflow design significantly improves output, maximizing vapor and the amount of cannabinoids, terpenes, and other active compounds. For those seeking the feel of a traditional smoking experience without the harshness of combustion, FLOW’s widened airpath delivers up to six times the airflow of previous models, for ultra-smooth, effortless hits.
Smarter, Simpler Use with Easy Loading and Cleaning
FLOW’s refined, side-mounted oven door is fully detachable and packs like a traditional pipe, enabling intuitive and seamless loading and accommodating 0.25g to 0.5g of cannabis flower. The redesigned oven, open-access airpath, and removable mouthpiece enable full visibility and accessibility for fast, no fuss-cleaning—no hidden residue or clogs.
Fast USB-C Charging and Sleek Magnetic Dock
The new USB-C charging port enables rapid charging, with a half charge in just 20 minutes and a full charge in as little as 40 minutes. Consumers can also opt for the FLOW Charging Stand (sold separately)—a precision-crafted, display-worthy dock that charges quickly while complementing FLOW’s modern form.
Iconic Design, Reimagined for Today’s Consumer
Backed by nearly two decades of award-winning design and engineering, FLOW strikes the perfect balance of power, efficiency, portability, and aesthetic. Compact yet robust, FLOW delivers the potency of a joint—with far more discretion—and no sidestream smoke or waste. As cannabis consumers evolve and increasingly demand connoisseurship, FLOW meets the moment with sophistication and a true-to-flower experience worthy of their standards.
Pricing and Availability
PAX FLOW will be available globally beginning August 5, 2025. Offered in Onyx and Greenstone, PAX FLOW retails for $350 and is available for purchase on pax.com/flow and at select retailers. Visit pax.com for more information.
PAX is a leading global cannabis brand on a mission to enhance people’s lives, honoring the power of the plant through pioneering innovation, peerless quality and premium design. For nearly two decades, PAX has delivered high-performance products—crafted for precision, purity and consistency—that are trusted by millions. PAX is committed to making a positive impact and PAX is certified Plastic Negative across all product lines by rePurpose Global.
© 2025 PAX Labs, Inc. All Rights Reserved. PAX, X, and ERA are all trademarks of PAX Labs, Inc. Patents and Trademarks: pax.com/IP.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805967305/en/
Contacts
press@pax.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom